CPB Budapest 2017

769 / 1609

16.4%
12%
Bartelink H. Lancet Oncol. 2015 Jan; 16(1):47-56
10.2%
6.2%
Boost vs
No Boost
EORTC
22881-10882
Trial
1989-1996
5318 T1-2
Free margins
Breast failure depends on the dose
50 Gy
66 Gy